Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients

BACKGROUND: It is currently not well described if a two‐dose regimen of a Covid‐19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. RESULTS: A total of 80 SOT recipients completed a two‐dose regimen with severe acute respiratory syndrome coronavirus 2 (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Holden, Inge K., Bistrup, Claus, Nilsson, Anna Christine, Hansen, Janne Fuglsang, Abazi, Rozeta, Davidsen, Jesper Rømhild, Poulsen, Mikael Kjær, Lindvig, Susan Olaf, Justesen, Ulrik S., Johansen, Isik Somuncu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447120/
https://www.ncbi.nlm.nih.gov/pubmed/34237179
http://dx.doi.org/10.1111/joim.13361
Descripción
Sumario:BACKGROUND: It is currently not well described if a two‐dose regimen of a Covid‐19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. RESULTS: A total of 80 SOT recipients completed a two‐dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine. CONCLUSION: This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid‐19 vaccination.

Ejemplares similares